Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice.

Cauwels A, Van Lint S, Catteeuw D, Pang S, Paul F, Rogge E, Verhee A, Prinz M, Kley N, Uzé G, Tavernier J.

J Autoimmun. 2019 Feb;97:70-76. doi: 10.1016/j.jaut.2018.10.010. Epub 2018 Nov 19.

PMID:
30467068
2.

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L, Rogge E, Verhee A, Uzé G, Tavernier J.

Oncoimmunology. 2017 Nov 27;7(3):e1398876. doi: 10.1080/2162402X.2017.1398876. eCollection 2018.

3.

Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, Rogge E, Verhee A, Vandekerckhove B, Kley N, Uzé G, Tavernier J.

Cancer Res. 2018 Jan 15;78(2):463-474. doi: 10.1158/0008-5472.CAN-17-1980. Epub 2017 Nov 29.

4.

Analyzing trapped protein complexes by Virotrap and SFINX.

Titeca K, Van Quickelberghe E, Samyn N, De Sutter D, Verhee A, Gevaert K, Tavernier J, Eyckerman S.

Nat Protoc. 2017 May;12(5):881-898. doi: 10.1038/nprot.2017.014. Epub 2017 Mar 30.

PMID:
28358392
5.

Trapping mammalian protein complexes in viral particles.

Eyckerman S, Titeca K, Van Quickelberghe E, Cloots E, Verhee A, Samyn N, De Ceuninck L, Timmerman E, De Sutter D, Lievens S, Van Calenbergh S, Gevaert K, Tavernier J.

Nat Commun. 2016 Apr 28;7:11416. doi: 10.1038/ncomms11416.

6.

Leptin's metabolic and immune functions can be uncoupled at the ligand/receptor interaction level.

Zabeau L, Jensen CJ, Seeuws S, Venken K, Verhee A, Catteeuw D, van Loo G, Chen H, Walder K, Hollis J, Foote S, Morris MJ, Van der Heyden J, Peelman F, Oldfield BJ, Rubio JP, Elewaut D, Tavernier J.

Cell Mol Life Sci. 2015 Feb;72(3):629-644. doi: 10.1007/s00018-014-1697-x. Epub 2014 Aug 7.

7.

Selection of non-competitive leptin antagonists using a random nanobody-based approach.

Zabeau L, Verhee A, Catteeuw D, Faes L, Seeuws S, Decruy T, Elewaut D, Peelman F, Tavernier J.

Biochem J. 2012 Jan 1;441(1):425-34. doi: 10.1042/BJ20110438.

PMID:
21851341
8.

Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.

Lavens D, Peelman F, Van der Heyden J, Uyttendaele I, Catteeuw D, Verhee A, Van Schoubroeck B, Kurth J, Hallenberger S, Clayton R, Tavernier J.

Nucleic Acids Res. 2010 Apr;38(6):1902-12. doi: 10.1093/nar/gkp1154. Epub 2009 Dec 16.

9.

MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells.

Pattyn E, Lavens D, Van der Heyden J, Verhee A, Lievens S, Lemmens I, Hallenberger S, Jochmans D, Tavernier J.

J Virol Methods. 2008 Oct;153(1):7-15. doi: 10.1016/j.jviromet.2008.06.021. Epub 2008 Jul 30.

PMID:
18640157
10.

HyperISGylation of Old World monkey ISG15 in human cells.

Pattyn E, Verhee A, Uyttendaele I, Piessevaux J, Timmerman E, Gevaert K, Vandekerckhove J, Peelman F, Tavernier J.

PLoS One. 2008 Jun 18;3(6):e2427. doi: 10.1371/journal.pone.0002427.

11.

Mammalian protein-protein interaction trap (MAPPIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor.

Uyttendaele I, Lemmens I, Verhee A, De Smet AS, Vandekerckhove J, Lavens D, Peelman F, Tavernier J.

Mol Endocrinol. 2007 Nov;21(11):2821-31. Epub 2007 Jul 31.

PMID:
17666591
12.

Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells.

Eyckerman S, Lemmens I, Catteeuw D, Verhee A, Vandekerckhove J, Lievens S, Tavernier J.

Nat Methods. 2005 Jun;2(6):427-33.

PMID:
15908921
13.

Phosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter.

Roosbeek S, Peelman F, Verhee A, Labeur C, Caster H, Lensink MF, Cirulli C, Grooten J, Cochet C, Vandekerckhove J, Amoresano A, Chimini G, Tavernier J, Rosseneu M.

J Biol Chem. 2004 Sep 3;279(36):37779-88. Epub 2004 Jun 24.

14.

Mapping of the leptin binding sites and design of a leptin antagonist.

Peelman F, Van Beneden K, Zabeau L, Iserentant H, Ulrichts P, Defeau D, Verhee A, Catteeuw D, Elewaut D, Tavernier J.

J Biol Chem. 2004 Sep 24;279(39):41038-46. Epub 2004 Jun 21.

15.

Design and use of a mammalian protein-protein interaction trap (MAPPIT).

Eyckerman S, Lemmens I, Lievens S, Van der Heyden J, Verhee A, Vandekerckhove J, Tavernier J.

Sci STKE. 2002 Dec 10;2002(162):pl18.

PMID:
12476003
16.

Comparison of leptin- and interleukin-6-regulated expression of the rPAP gene family: evidence for differential co-regulatory signals.

Broekaert D, Eyckerman S, Lavens D, Verhee A, Waelput W, Vandekerckhove J, Tavernier J.

Eur Cytokine Netw. 2002 Jan-Mar;13(1):78-85.

17.

Design and application of a cytokine-receptor-based interaction trap.

Eyckerman S, Verhee A, der Heyden JV, Lemmens I, Ostade XV, Vandekerckhove J, Tavernier J.

Nat Cell Biol. 2001 Dec;3(12):1114-9.

PMID:
11781573
18.

Neutralizing monoclonal antibodies can potentiate IL-5 signaling.

Zabeau L, Van der Heyden J, Broekaert D, Verhee A, Vandekerckhove J, Wu SJ, Chaiken I, Heinrich P, Behrmann I, Tavernier J.

Eur J Immunol. 2001 Apr;31(4):1087-97.

19.

Effect of mutations of N- and C-terminal charged residues on the activity of LCAT.

Peelman F, Vanloo B, Verschelde JL, Labeur C, Caster H, Taveirne J, Verhee A, Duverger N, Vandekerckhove J, Tavernier J, Rosseneu M.

J Lipid Res. 2001 Apr;42(4):471-9.

20.

Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor.

Eyckerman S, Broekaert D, Verhee A, Vandekerckhove J, Tavernier J.

FEBS Lett. 2000 Dec 1;486(1):33-7.

21.

A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoproteins.

Desrumaux C, Labeur C, Verhee A, Tavernier J, Vandekerckhove J, Rosseneu M, Peelman F.

J Biol Chem. 2001 Feb 23;276(8):5908-15. Epub 2000 Nov 16.

22.

Headgroup specificity of lecithin cholesterol acyltransferase for monomeric and vesicular phospholipids.

Christiaens B, Vanloo B, Gouyette C, Van Vynckt I, Caster H, Taveirne J, Verhee A, Labeur C, Peelman F, Vandekerckhove J, Tavernier J, Rosseneu M.

Biochim Biophys Acta. 2000 Jul 19;1486(2-3):321-7.

PMID:
10903483
23.

Identification and expression analysis of leptin-regulated immediate early response and late target genes.

Waelput W, Verhee A, Broekaert D, Eyckerman S, Vandekerckhove J, Beattie JH, Tavernier J.

Biochem J. 2000 May 15;348 Pt 1:55-61.

24.

Relationship between structure and biochemical phenotype of lecithin:cholesterol acyltransferase (LCAT) mutants causing fish-eye disease.

Vanloo B, Peelman F, Deschuymere K, Taveirne J, Verhee A, Gouyette C, Labeur C, Vandekerckhove J, Tavernier J, Rosseneu M.

J Lipid Res. 2000 May;41(5):752-61.

25.

Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit.

Tavernier J, Van der Heyden J, Verhee A, Brusselle G, Van Ostade X, Vandekerckhove J, North J, Rankin SM, Kay AB, Robinson DS.

Blood. 2000 Mar 1;95(5):1600-7.

PMID:
10688814
26.

A sensitive and versatile bioassay for ligands that signal through receptor clustering.

Van Ostade X, Schauvliege L, Pattyn E, Verhee A, Vandekerckhove J, Tavernier J.

J Interferon Cytokine Res. 2000 Jan;20(1):79-87.

PMID:
10670654
27.

Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line.

Eyckerman S, Waelput W, Verhee A, Broekaert D, Vandekerckhove J, Tavernier J.

Eur Cytokine Netw. 1999 Dec;10(4):549-56.

28.

Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity.

Pattyn E, Van Ostade X, Schauvliege L, Verhee A, Kalai M, Vandekerckhove J, Tavernier J.

J Biol Chem. 1999 Dec 3;274(49):34838-45.

29.
30.

Characterization of functional residues in the interfacial recognition domain of lecithin cholesterol acyltransferase (LCAT).

Peelman F, Vanloo B, Perez-Mendez O, Decout A, Verschelde JL, Labeur C, Vinaimont N, Verhee A, Duverger N, Brasseur R, Vandekerckhove J, Tavernier J, Rosseneu M.

Protein Eng. 1999 Jan;12(1):71-8.

PMID:
10065713
31.

A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling.

Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde JL, Labeur C, Seguret-Mace S, Duverger N, Hutchinson G, Vandekerckhove J, Tavernier J, Rosseneu M.

Protein Sci. 1998 Mar;7(3):587-99.

32.

Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

Tavernier J, Tuypens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J, Guisez Y, Oefner C.

Proc Natl Acad Sci U S A. 1995 May 23;92(11):5194-8.

33.

Recombinant soluble human interleukin-5 (hIL-5) receptor molecules. Cross-linking and stoichiometry of binding to IL-5.

Devos R, Guisez Y, Cornelis S, Verhee A, Van der Heyden J, Manneberg M, Lahm HW, Fiers W, Tavernier J, Plaetinck G.

J Biol Chem. 1993 Mar 25;268(9):6581-7.

34.

Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit.

Tavernier J, Tuypens T, Plaetinck G, Verhee A, Fiers W, Devos R.

Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7041-5.

Supplemental Content

Loading ...
Support Center